Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 20,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $98.77, for a total value of $1,975,400.00. Following the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $98,770. This represents a 95.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total value of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $102.27, for a total value of $2,045,400.00.

Billiontoone Stock Performance

BLLN traded up $0.26 during trading hours on Friday, hitting $98.77. 406,007 shares of the stock were exchanged, compared to its average volume of 543,328. The stock has a market cap of $4.66 billion and a price-to-earnings ratio of 141.10. The stock has a 50-day simple moving average of $112.07 and a 200-day simple moving average of $95.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting the consensus estimate of $0.15. The firm had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. Analysts anticipate that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently modified their holdings of BLLN. UBS Group AG acquired a new stake in shares of Billiontoone in the 4th quarter worth about $2,586,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Billiontoone in the 4th quarter valued at about $82,000. Geode Capital Management LLC acquired a new position in Billiontoone during the 4th quarter valued at about $6,716,000. Seven Grand Managers LLC acquired a new position in Billiontoone during the 4th quarter valued at about $2,046,000. Finally, Norges Bank bought a new position in Billiontoone in the 4th quarter worth about $818,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Canaccord Genuity Group initiated coverage on shares of Billiontoone in a report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 target price on the stock. Guggenheim began coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 target price for the company. Zacks Research lowered Billiontoone from a “hold” rating to a “strong sell” rating in a report on Monday, August 31st. Finally, BTIG Research dropped their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $125.88.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.